The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are α-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention relates to a hybrid material comprising a perovskite and a singlet fission compound. The hybrid material comprises layers of the perovskite in which the singlet fission compound occupies an interlayer space of the perovskite structure. The hybrid material may be useful as a semiconductor, e.g., in a photovoltaic cell. Also disclosed are processes for preparing the hybrid material and components comprising the hybrid material, such as a photovoltaic cell.
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
C09K 11/66 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
H01L 31/0248 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs
3.
HIGH-TEMPERATURE SUPERCONDUCTING SWITCHES AND RECTIFIERS
There is provided a rectifier of an alternating input current, which may comprise: an electrical switch comprising a length of HITS material to carry an alternating switch current, the HITS material having a critical current: a magnetic field generator to apply a magnetic field to the HTS material: a control mechanism to control the magnetic field generator to switch the switch between a low-resistance state when a magnitude of the magnetic field is relatively low and a higher-resistance state when a magnitude of the magnetic field is relatively high, the relatively high magnitude being sufficient to reduce the critical current so that, for a part of the alternating switch current cycle, the current approaches the critical current, is substantially equal to the critical current or is greater than the critical current. There is further provided an electrical switch having two strands of superconducting material arranged in a bifilar arrangement.
H03K 17/92 - Commutation ou ouverture de porte électronique, c.-à-d. par d'autres moyens que la fermeture et l'ouverture de contacts caractérisée par l'utilisation de composants spécifiés par l'utilisation, comme éléments actifs, de dispositifs supraconducteurs
H01F 7/06 - Électro-aimantsActionneurs comportant des électro-aimants
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV):
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV):
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07H 19/10 - Radicaux pyrimidine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques
5.
IMPROVEMENTS IN CONTROL OF CURRENT SUPPLY TO A TRANSFORMER-RECTIFIER FLUX PUMP
The technology relates to the field of superconductor transformer-rectifier flux pumps and controlling a supply of alternating current to a transformer-rectifier flux pump to charge a load. A response of the transformer-rectifier flux pump to a characterisation current supply is determined, which may comprise determining values in the flux pump corresponding to values of the applied current. For each of a plurality of target values of load current to be supplied to the load, values of the current supply are calculated. The supply of current to the flux pump is controlled accordingly. The supply may be modified based on feedback received from the flux pump, for example sensors measuring values on the secondary side of the transformer.
H01F 27/40 - Association structurelle de composants électriques incorporés, p. ex. fusibles
H01F 41/04 - Appareils ou procédés spécialement adaptés à la fabrication ou à l'assemblage des aimants, des inductances ou des transformateursAppareils ou procédés spécialement adaptés à la fabrication des matériaux caractérisés par leurs propriétés magnétiques pour la fabrication de noyaux, bobines ou aimants pour la fabrication de bobines
H01H 36/00 - Interrupteurs actionnés par la variation du champ magnétique ou champ électrique, p. ex. par le changement de la position relative d'un aimant et d'un interrupteur, par écran
H02H 7/00 - Circuits de protection de sécurité spécialement adaptés aux machines ou aux appareils électriques de types particuliers ou pour la protection sectionnelle de systèmes de câble ou de ligne, et effectuant une commutation automatique dans le cas d'un changement indésirable des conditions normales de travail
H02M 7/02 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continu sans possibilité de réversibilité
The present invention relates to improvements in scanning electrochemical microscopy. The device includes a probe configured with two barrels: the first barrel configured to hold a liquid solution and a probe electrode; and the second barrel configured to hold a gas and an inlet connectable to a gas supply. The probe is shaped into a scanning tip formed at distal ends of the first and second barrels, and the device may further include a gas controller to control pressure and/or flow rate of the gas to the second barrel of the probe. The device may further include a reference electrode configured for use in the liquid solution, and a counter electrode configured for use in the liquid solution.
G01N 27/403 - Ensembles de cellules et d'électrodes
G01N 13/00 - Recherche des effets de surface ou de couche limite, p. ex. pouvoir mouillantRecherche des effets de diffusionAnalyse des matériaux en déterminant les effets superficiels, limites ou de diffusion
G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
G01N 27/404 - Cellules avec l'anode, la cathode et l'électrolyte de la cellule du même côté d'une membrane perméable qui les sépare du fluide de l'échantillon
G01Q 30/04 - Dispositifs d'affichage ou de traitement de données
G01Q 60/60 - Microscopie électrochimique à balayage SECM [Scanning Electro-Chemical Microscopy] ou appareils à cet effet, p. ex. sondes SECM
Some previously proposed technologies may not quickly and effectively locate and manage faults in an electricity network, such as high impedance faults. Disclosed herein is a method for determining a fault location in an electricity distribution network. Such a method may comprise receiving one or more electrical signals (e.g. voltage or current signals) obtained from one or more measurement locations at the electricity distribution network. The one or more electrical signals may have been influenced by a fault at the network. The method may decompose each electrical signal to derive one or more constituent frequency components. Such constituent frequency components may be constructable to approximate (or estimate) the electrical signal. The method may provide a circuit model of a portion of the electricity distribution network. Such circuit model may comprise an expected fault location. The method may establish one or more predicted relationships between the fault location and the electrical signals using the circuit model. The method may derive one or more estimated fault locations to determine the fault location in the electricity distribution network. The method may derive each estimated fault location from a predicted relationship using a constituent frequency component decomposed from each of the respective electrical signals in the predicted relationship.
G01R 27/16 - Mesure de l'impédance d'un élément ou d'un réseau dans lequel passe un courant provenant d'une autre source, p. ex. câble, ligne de transport de l'énergie
G01R 27/28 - Mesure de l'atténuation, du gain, du déphasage ou des caractéristiques qui en dérivent dans des réseaux électriques quadripoles, c.-à-d. des réseaux à double entréeMesure d'une réponse transitoire
Aspects of the technology provide a method / system of sensing a change in temperature and/or strain in an optical fibre comprising a substantially continuous or quasi-continuous fibre Bragg grating. A difference spectrum is determined between a reference reflected spectrum of the fibre Bragg grating and a monitored reflected spectrum. The difference spectrum is analysed to determine whether the optical fibre is experiencing a change of type a) – a temperature increase or an extension – or of type b) – a temperature decrease or a contraction. The technology may be applied to sensing a change in temperature and/or strain in a superconductor or detecting a risk of a quench in a superconductor.
G01K 11/3206 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant des changements dans la transmittance, la diffusion ou la luminescence dans les fibres optiques en des endroits distincts de la fibre, p. ex. utilisant la diffusion de Bragg
G01B 11/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la déformation dans un solide, p. ex. indicateur optique de déformation
G01D 1/16 - Dispositions pour la mesure donnant des résultats autres que la valeur instantanée d'une variable, d'application générale donnant une valeur qui est une fonction de plusieurs valeurs, p. ex. produit ou rapport
G01D 5/26 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensibleMoyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminéTransducteurs non spécialement adaptés à une variable particulière utilisant des moyens optiques, c.-à-d. utilisant de la lumière infrarouge, visible ou ultraviolette
There is provided an electrical switch comprising a length of superconducting material. In some forms the electrical switch is configured to be controlled between a low-resistance state and a higher-resistance state by the selective application of one or more switching mechanisms. In the higher-resistance state, current flowing through the length of superconducting material may approach the critical current of the length of superconducting material, may be substantially equal to the critical current or may be greater than the critical current. In some forms, the length of superconducting material is a length of high temperature superconducting material. The switching mechanisms may comprise: heating the length of superconducting material; applying a magnetic field to the length of superconducting material; applying a time-varying magnetic field to create dynamic resistance and/or heat; and/or applying a time-varying magnetic field to a loop of superconducting material to create a screening current around the loop.
The invention relates to a device for inducing a current flow in a load, also referred to as a flux pump. The device may comprise a rotor comprising at least one magnetic field generator configured to rotate with the rotor, one or more lengths of superconducting material arranged as an induction coil, a switch, and output terminals configured to connect to a load, the output terminals being connected in parallel with the switch. Rotation of the rotor may move the at least one magnetic field generator relative to the induction coil and switch, such that the magnetic field is periodically applied to the induction coil and switch to induce a current flow in the induction coil through the switch, and to reduce a critical current of the material within the switch, causing the switch to transition from a low-resistance state to a higher-resistance state.
G01R 33/3815 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des électro-aimants avec des bobines supraconductrices, p. ex. leurs alimentations
The technology relates to electrical devices comprising a length of superconducting material with a critical current when current travels in one direction is different to a critical current of the length of superconducting material when current travels through the length of superconducting material in an opposite direction. The electrical device may further comprise a magnetic field generator comprising two permanent magnets positioned on the same side of the length of superconducting material and arranged substantially anti-parallel to each other. The polar axes of the two permanent magnets may be oriented substantially perpendicular to the faces of the length of superconducting material.
H10N 60/30 - Dispositifs commutables entre les états supraconducteur et normal
G01R 33/02 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques
H01F 6/02 - Étouffement de la supraconductivitéDispositions pour la protection lors de la phase de transition vers l'état de conductivité normale
H01F 6/06 - Bobines, p. ex. dispositions pour l'enroulement, l'isolation, les enveloppes ou les bornes des bobines
H01F 13/00 - Appareils ou procédés pour l'aimantation ou pour la désaimantation
H02M 1/00 - Détails d'appareils pour transformation
H03K 17/92 - Commutation ou ouverture de porte électronique, c.-à-d. par d'autres moyens que la fermeture et l'ouverture de contacts caractérisée par l'utilisation de composants spécifiés par l'utilisation, comme éléments actifs, de dispositifs supraconducteurs
H03K 19/195 - Circuits logiques, c.-à-d. ayant au moins deux entrées agissant sur une sortieCircuits d'inversion utilisant des éléments spécifiés utilisant des dispositifs supraconducteurs
H10N 60/20 - Dispositifs à supraconductivité permanente
C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons
C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
14.
AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are a-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7008 - Composés ayant un groupe amino lié directement à un atome de carbone du radical saccharide, p. ex. D-galactosamine, ranimustine
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C07H 15/14 - Radicaux acycliques non substitués par des structures cycliques liés à un atome de soufre, de sélénium ou de tellure d'un radical saccharide
Biosensor systems for detecting levels of nitrogen-containing molecules are provided. Further provided are biosensor system components and various detection platforms, methods, and kits.
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
17.
RNA LIGASE ENZYMES AND METHODS OF PREPARATION AND USE THEREOF
The present disclosure encompasses RNA ligase enzymes, particularly thermostable RNA ligase enzymes, and including variant enzymes, along with the preparation and use thereof. Specifically encompassed are methods for preparing the RNA ligase enzymes, methods for ligation using these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07H 15/18 - Radicaux acycliques substitués par des carbocycles
C07H 13/08 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés directement à des carbocycles
A method for generating a saliency map for use in polygon reduction, including: processing a 3D object file of an object by storing vertices of meshes of the object in a data structure; determining a tropical angle of curvature for each vertex within a geodesic radius, wherein the tropical angle of curvature represents a difference in angles of normal vectors at all vertices connected to the vertex by a mesh edge; and generating a saliency value for each vertex for the saliency map based on the tropical angle of curvature.
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.
Disclosed are a cathode materials suitable for an aluminium ion battery, wherein the cathode materials comprise a main group element nitride, and an oxide of a main group element or an oxide of a element in Group 1 to 13. The nitride is preferably a 2-dimensional layered material. Preferably, the ratio of the main group element nitride to the oxide is between 5:95 and 95:5 (by weight).
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
H01M 4/46 - Alliages à base de magnésium ou d'aluminium
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 50/46 - Séparateurs, membranes ou diaphragmes caractérisés par leur combinaison avec des électrodes
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p. ex. au magnésium ou à l'aluminium
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 31/14 - Antiviraux pour le traitement des virus ARN
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
A polymer composition for impregnating a high temperature superconductor (HTS) coil, the composition comprising: a polymer resin, a plurality of particles of a first filler material, and a plurality of particles of a second filler material; wherein the median particle size of the second filler material is less than the median particle size of the first filler material. The polymer composition may be used to prepare a polymer impregnated HTS coil having a predetermined turn-to-turn spacing. A property of the polymer composition may also be modified, for example, the coefficient of thermal contraction and/or resistivity of the composition. Also disclosed is a polymer impregnated HTS coil and a method for preparing the coil.
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV).
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))
The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The present invention encompasses non-ribosomal peptides and non-ribosomal peptide synthetases, and the preparation and use thereof. Specifically encompassed are methods for preparing non-ribosomal peptide synthetases, methods for preparing non-ribosomal peptides from these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
The invention relates to a stabilising head support for use by a patient during MRI scanning. The head support includes a shell and an inflatable bladder that is located at least partially within the shell. During use, the shell is located within an MRI magnet and the bladder is inflated about the patients head to help hold the head steady during imaging.
Described herein is a process for hydroarylation of an olefin to obtain an alkylated benzene product. The process involves reacting an olefin compound of formula II with an arene compound of formula III in the presence of a lanthanide complex, e.g. a lanthanide (II) hydride complex. Also described herein is a lanthanide complex and process for the preparation thereof.
The present disclosure relates to the field of medical applications. In particular, to a measurement system and method for non-invasive detection and monitoring of physiological parameters, in particular perfusion, to provide clinically relevant information through Nuclear Magnetic Resonance (NMR) observation.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
32.
HIGH-TEMPERATURE SUPERCONDUCTING SWITCHES AND RECTIFIERS
There is provided a rectifier of an alternating input current, which may comprise: an electrical switch comprising a length of HTS material to carry an alternating switch current, the HTS material having a critical current; a magnetic field generator to apply a magnetic field to the HTS material; a control mechanism to control the magnetic field generator to switch the switch between a low-resistance state when a magnitude of the magnetic field is relatively low and a higher-resistance state when a magnitude of the magnetic field is relatively high, the relatively high magnitude being sufficient to reduce the critical current so that, for a part of the alternating switch current cycle, the current approaches the critical current, is substantially equal to the critical current or is greater than the critical current. There is further provided an electrical switch having two strands of superconducting material arranged in a bifilar arrangement.
H02M 5/293 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant alternatif, p. ex. pour changement de la tension, pour changement de la fréquence, pour changement du nombre de phases sans transformation intermédiaire en courant continu par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 7/217 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continu sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 7/48 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande
H02P 9/30 - Dispositions pour la commande de génératrices électriques de façon à obtenir les caractéristiques désirées à la sortie par variation du champ utilisant des tubes à décharge ou des dispositifs à semi-conducteurs utilisant des dispositifs à semi-conducteurs
G01R 33/383 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des aimants permanents
H01F 27/42 - Circuits spécialement adaptés à la modification ou la compensation des caractéristiques électriques des transformateurs, réactances ou bobines d'arrêt
H01H 36/00 - Interrupteurs actionnés par la variation du champ magnétique ou champ électrique, p. ex. par le changement de la position relative d'un aimant et d'un interrupteur, par écran
H02K 55/06 - Machines dynamo-électriques comportant des enroulements qui fonctionnent à des températures cryogéniques du type homopolaire
H02M 1/00 - Détails d'appareils pour transformation
H03K 17/92 - Commutation ou ouverture de porte électronique, c.-à-d. par d'autres moyens que la fermeture et l'ouverture de contacts caractérisée par l'utilisation de composants spécifiés par l'utilisation, comme éléments actifs, de dispositifs supraconducteurs
H01F 13/00 - Appareils ou procédés pour l'aimantation ou pour la désaimantation
H02M 7/00 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continuTransformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif
There is provided an electrical switch comprising a length of superconducting material. In some forms the electrical switch is configured to be controlled between a low-resistance state and a higher-resistance state by the selective application of one or more switching mechanisms. In the higher-resistance state, current flowing through the length of superconducting material may approach the critical current of the length of superconducting material, may be substantially equal to the critical current or may be greater than the critical current. In some forms, the length of superconducting material is a length of high temperature superconducting material. The switching mechanisms may comprise: heating the length of superconducting material; applying a magnetic field to the length of superconducting material; applying a time-varying magnetic field to create dynamic resistance and/or heat; and/or applying a time-varying magnetic field to a loop of superconducting material to create a screening current around the loop.
H01L 39/10 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par les moyens de commutation
H01L 39/16 - Dispositifs commutables entre les états normal et supraconducteur
H03K 17/92 - Commutation ou ouverture de porte électronique, c.-à-d. par d'autres moyens que la fermeture et l'ouverture de contacts caractérisée par l'utilisation de composants spécifiés par l'utilisation, comme éléments actifs, de dispositifs supraconducteurs
VICTORIA UNIVERSITY OF WELLINGTON (Nouvelle‑Zélande)
Inventeur(s)
Godfrey, Dale Ian
Heath, William Ross
Holz, Lauren Eelise
Hermans, Ian Francis
Painter, Gavin Frank
Anderson, Regan James
Copton, Benjamin Jason
Gulab, Shivali Ashwin
Abrégé
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
C07C 229/38 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques et des groupes carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné
C07C 323/62 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des groupes carboxyle liés au même squelette carboné ayant l'atome de soufre d'au moins un des groupes thio lié à un atome de carbone d'un cycle aromatique à six chaînons du squelette carboné
Disclosed are electrolyte compositions for electrochemical devices, where the electrolyte compositions comprise a microemulsion and where the microemulsion comprises an aqueous phase and a water-immiscible phase. Also disclosed are microemulsion electrolyte compositions for electrically rechargeable electrochemical energy storage devices, including ion batteries (such as lithium ion, sodium ion, magnesium ion, calcium ion, and aluminium ion batteries), redox flow batteries and supercapacitors.
LANDCARE RESEARCH NEW ZEALAND LIMITED (Nouvelle‑Zélande)
VICTORIA LINK LTD (Nouvelle‑Zélande)
Inventeur(s)
Garvey, Patrick
Jackson, Michael David
Linklater, Wayne Leslie
Abrégé
The invention relates to mammalian attractants and to the use of such attractants in baits and traps for killing, capturing and/or monitoring mammalian targets; in particular mustelids.
A01N 63/10 - Animaux Substances produites par des animaux ou obtenues à partir de ceux-ci
A01N 27/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des hydrocarbures
A01N 35/02 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde contenant des groupes aldéhyde ou cétone, ou leurs thio-analogues, liés aliphatiquementLeurs dérivés, p. ex. acétals
The invention provides compounds of the Formula (I) or the Formula (Ia) which are useful intermediates in the synthesis of potential antiviral drugs such as 3'-deoxy-3',4'-didehydro-cytidine triphosphate (ddhCTP).
Propulsion mechanisms, other than for land vehicles;
apparatus for the propulsion of spacecraft or aircraft,
thrusters, ion thrusters; electric generators,
superconducting generators; electric motors (other than for
land vehicles), superconducting motors; dynamos, flux pumps,
superconducting dynamos, flux pumps; bearings,
superconducting bearings. Apparatus and installations for heating or cooling; heating
and cooling apparatus for use in spacecraft or aircraft;
cryocooling apparatus; cryogenic apparatus; cryostats, other
than for laboratory use.
40.
ELECTRICITY DISTRIBUTION NETWORK FAULT DETECTION SYSTEM AND METHOD
An electricity distribution network fault detector 122 is provided. The fault detector may comprise a signal processor 124 configured to perform signal processing on magnetic field data, the magnetic field data representing at least one magnetic field generated by at least one electricity distribution line 112; a data selector 126 configured to receive transformed magnetic field data from the signal processor 124 and to select a time window of the received data; and a classifier 128 configured to receive at least one time window from the data selector 126 and to apply a classification to the at least one time window, the classification selected from a group of classifications.
(1) Electric and electromagnetic and chemical-electromagnetic hybrid and laser propulsion mechanisms, other than for land vehicles, namely, laser ablation propulsion mechanisms, magnetoplasmadynamic propulsion mechanisms; apparatus for the propulsion of spacecraft or aircraft, namely, rocket thrusters, ion rocket thrusters; electric generators, superconducting generators; electric motors and superconducting motors for spacecraft and aircraft; dynamos, electric flux pumps, superconducting dynamos; levitated disc bearings, superconducting disc bearings.
(2) Apparatus and installations for heating or cooling, namely, cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; heating and cooling apparatus for use in spacecraft or aircraft; cryocooling apparatus, namely, cryocoolers; cryogenic apparatus, namely, cryocoolers, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations; cryostats, other than for laboratory use.
Electric and electromagnetic and chemical-electromagnetic hybrid and laser propulsion mechanisms, other than for land vehicles, namely, laser ablation propulsion mechanisms, magnetoplasmadynamic propulsion mechanisms; electric generators, superconducting generators; electric motors other than for land vehicles, superconducting motors other than for land vehicles; dynamos, electromagnetic flux pumps, superconducting dynamos, electric flux pumps; levitated disc bearings, superconducting disc bearings Apparatus and installations for heating or cooling, namely cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; heating and cooling apparatus for use in spacecraft or aircraft, namely cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; cryocooling apparatus, namely cryocoolers; cryogenic apparatus, namely cryocoolers, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations; cryostats, other than for laboratory use, namely cryostats for electromagnets, cryostats for electromagnetic detectors
43.
AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Catalysts; catalysts for use in chemical processes;
catalysts for use in the manufacture of industrial
chemicals; ammonia; ammonia water; ammonia for industrial
purposes; anhydrous ammonia; chemical preparations for
scientific purposes, other than for medical or veterinary
use; chemical preparations for use in industry; chemical
reagents for scientific purposes; chemicals for industrial
use; chemicals for use in industry and science; chemicals
for use in the purification of water; chemicals for use in
the treatment of water; chemicals used in agriculture;
ammonia [volatile alkali] for industrial purposes; volatile
alkali [ammonia] for industrial purposes; rare earth
compounds; rare earth nitrides. Processing of raw materials; production and processing of
fuels and of other sources of energy; application of thin
films on the surfaces of objects by means of chemical,
mechanical, thermal, thermomechanical, chemical vapor
deposition, physical vapor deposition and vacuum deposition
processes; application of thin films on the surfaces of
objects by means of chemical, mechanical, thermal,
thermomechanical, chemical vapour deposition, physical
vapour deposition and vacuum deposition processes;
processing of chemicals and petrochemicals; processing of
fuel materials; processing of fuels; processing of gas;
processing of materials; production of energy by power
plants; production of energy; production and generation of
ammonia; production and generation of ammonia using rare
earth materials; provision of information, consultancy and
advice in relation to the aforesaid services; consultancy in
the field of energy production. Development of industrial processes; industrial process
development; scientific research in the field of renewable
energy; scientific research in the field of energy;
consultancy in the field of chemistry; consultancy in the
field of energy efficiency; consultancy in the field of
industrial research; consultancy in the field of industrial
process development; provision of information, consultancy
and advice in relation to the aforesaid services.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Rare earth catalysts for use in chemical processes; catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; rare earth catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; chemical reagents for scientific purposes; chemicals for use in industrial processing; chemicals for use in industry and science; chemicals for use in the purification of water; chemicals for use in the treatment of water; ammonia in the nature of volatile alkali for industrial processing; volatile alkali in the nature of ammonia for industrial processing; rare earth compounds; rare earth nitrides Processing of raw materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials, rare earth nitrides; production and processing of fuels and of other sources of energy; application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapor deposition, physical vapor deposition and vacuum deposition processes; application of thin films of rare earth materials on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes; application of rare earth nitrides on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes; processing of chemicals and petrochemicals; processing of fuel materials; processing of fuels; processing of natural gas; processing of materials namely hydrogen, nitrogen, ammonia, rare earth materials, rare earth nitrides; production of energy by power plants; production of energy; production and generation of ammonia; production and generation of ammonia using rare earth materials; provision of information, consultancy and advice in relation to the aforesaid services Development of industrial processes in the field of ammonia manufacture; industrial process development field of ammonia manufacture; scientific research in the field of renewable energy; scientific research in the field of energy; consultancy in the field of chemistry; consultancy in the field of energy efficiency; consultancy in the field of industrial research; consultancy in the field of industrial process development; provision of information, consultancy and advice in the field of the foregoing services
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Bio-chemical catalysts; catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; rare earth catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; catalysts for use in the manufacture of industrial chemicals; ammonia volatile alkali for industrial processes; ammonia water; anhydrous ammonia; chemicals for use in the purification of water; chemicals for use in the treatment of water; chemicals used in agriculture; ammonia [volatile alkali] for industrial purposes; volatile alkali [ammonia] for industrial purposes; rare earth compounds; rare earth nitrides. (1) Processing of raw materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials and rare earth nitrides, production and processing of fuels and of other sources of energy, application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapor deposition, physical vapor deposition and vacuum deposition processes, application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes, processing of chemicals and petrochemicals, processing of fuel materials, processing of fuels, processing of gas, processing of materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials and rare earth nitrides, production of energy by power plants, production of energy, production and generation of ammonia, production and generation of ammonia using rare earth materials, provision of information, consultancy and advice in relation to the aforesaid services, consultancy in the field of energy production.
(2) Development of industrial processes in the field of ammonia manufacture, industrial process development in the field of ammonia manufacture, scientific research in the field of renewable energy, scientific research in the field of energy, consultancy in the field of chemistry, consultancy in the field of energy efficiency, consultancy in the field of industrial research in relation to ammonia manufacture, consultancy in the field of industrial process development in relation to ammonia manufacture, provision of information, consultancy and advice in relation to the aforesaid services.
An optical fibre sensing system (300) with an incident light source (309), a wavelength spectrum interrogator (313), and an optical fibre (302) with a substantially continuous fibre Bragg grating (306). An upstream portion (318) of the optical fibre has an attenuation length to light to the interrogator (313) at a first equilibrium wavelength. A downstream portion (322) of the optical fibre reflects light to the interrogator (313) when a change in temperature and/or strain at the downstream portion (322) causes a portion of the fibre Bragg grating to reflect light to the interrogator (313) at a second wavelength and at a second intensity. A processor (315) is configured to analyse the reflected spectrum (314) to determine when a portion of the fibre Bragg grating (306) is experiencing a change in temperature and/or strain based on deviation in the reflected spectrum (314) from an initial peak corresponding to the initial wavelength.
G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p. ex. par l'analyse des contraintes par photo-élasticité
G01B 11/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la déformation dans un solide, p. ex. indicateur optique de déformation
G01K 1/16 - Dispositions particulières pour conduire la chaleur de l'objet à l'élément sensible
G01K 11/3206 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant des changements dans la transmittance, la diffusion ou la luminescence dans les fibres optiques en des endroits distincts de la fibre, p. ex. utilisant la diffusion de Bragg
H01F 6/02 - Étouffement de la supraconductivitéDispositions pour la protection lors de la phase de transition vers l'état de conductivité normale
49.
Inhibitors of DNMT1 as anticancer therapeutic agents
Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1. The inhibitors are compounds of the general formula:
An asymmetric magnet for use in performing MRI of a patient's head. The magnet has a patient end. The magnet provides an offset imaging volume (35) in a recess with an isocentre that is positioned closer to the patient end than an opposite end. The magnet has at least three groups of coils (44, 45, 46) in a generally tapering arrangement. The magnet also has an additional group of coils (47). A first group of coils (44) overlaps the additional group of coils (47), such that a bottom portion (47″) of the additional group of coils (47) is positioned closer to the patient end of the magnet than a top portion (44′) of the first group of coils (44).
G01R 33/00 - Dispositions ou appareils pour la mesure des grandeurs magnétiques
G01R 33/34 - Détails de structure, p. ex. résonateurs
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/38 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient
Disclosed are a cathode materials suitable for an aluminium ion battery, wherein the cathode materials comprise a main group element nitride, and an oxide of a main group element or an oxide of a element in Group 1 to 13. The nitride is preferably a 2-dimensional layered material. Preferably, the ratio of the main group element nitride to the oxide is between 5:95 and 95:5 (by weight).
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p. ex. au magnésium ou à l'aluminium
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
C07H 13/08 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés directement à des carbocycles
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07H 15/18 - Radicaux acycliques substitués par des carbocycles
53.
METHOD OF PERFORMING A DISTRIBUTED TASK OVER A NETWORK
An aspect of the invention provides a method of performing a distributed task over a network comprising a plurality of nodes. The method comprises: a plurality of network nodes observing (300) data; applying a first linear code function to the data observed by at least one network node of the plurality of network nodes to obtain (302) at least one function output; applying errors (304) to the at least one function output; a query node selected from the network nodes performing (308) a mixing procedure to aggregate node observations to obtain a first set of aggregated values until a stopping criteria (306) is satisfied; applying (312) a second linear code function to the set of aggregated values to obtain a second set of aggregated values returned to their observed domain; and the query node outputting (314) the second set of aggregated values.
H04W 84/18 - Réseaux auto-organisés, p. ex. réseaux ad hoc ou réseaux de détection
H04W 72/02 - Sélection de ressources sans fil par un utilisateur ou un terminal
G16Y 20/00 - Information détectée ou collectée par les objets
H03M 13/00 - Codage, décodage ou conversion de code pour détecter ou corriger des erreursHypothèses de base sur la théorie du codageLimites de codageMéthodes d'évaluation de la probabilité d'erreurModèles de canauxSimulation ou test des codes
54.
A PROCESS FOR LIGHTING AND COMPOSITING AN OBJECT INTO AN IMAGE
A process for representing light in a scene that includes receiving an image of the scene, which may only be a partial view of the scene. The image is applied to at least one convolutional neural network (CNN) that generates reflectance maps of the scene for respective roughness levels. The process can then select at least one of the reflectance maps based on a roughness level of an object in the image, and light and composite the object into the image using the selected at least one of the reflectance maps.
The present application relates to semiochemical-based lures for mammals, particularly mammalian pest species that are useful for monitoring, capturing and/or controlling mammals and to methods of using semiochemical-based lures for monitoring, capturing and/or controlling mammals, particularly mammalian pest species. The present application also relates to the use of semiochemical-based lures for monitoring, capturing and/or controlling mammals, particularly mammalian pest species. In some embodiments, semiochemical-based lures are useful for reducing the number of mammalian pest species in one or more designated target environments.
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
A01N 27/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des hydrocarbures
A01N 35/02 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde contenant des groupes aldéhyde ou cétone, ou leurs thio-analogues, liés aliphatiquementLeurs dérivés, p. ex. acétals
A01N 37/02 - Acides carboxyliques saturés ou leurs thio-analoguesLeurs dérivés
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
G01R 33/035 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs supraconducteurs
H01F 6/06 - Bobines, p. ex. dispositions pour l'enroulement, l'isolation, les enveloppes ou les bornes des bobines
H02H 7/00 - Circuits de protection de sécurité spécialement adaptés aux machines ou aux appareils électriques de types particuliers ou pour la protection sectionnelle de systèmes de câble ou de ligne, et effectuant une commutation automatique dans le cas d'un changement indésirable des conditions normales de travail
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
H01L 39/16 - Dispositifs commutables entre les états normal et supraconducteur
G01R 33/035 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs supraconducteurs
H01F 6/06 - Bobines, p. ex. dispositions pour l'enroulement, l'isolation, les enveloppes ou les bornes des bobines
H02H 7/00 - Circuits de protection de sécurité spécialement adaptés aux machines ou aux appareils électriques de types particuliers ou pour la protection sectionnelle de systèmes de câble ou de ligne, et effectuant une commutation automatique dans le cas d'un changement indésirable des conditions normales de travail
The invention relates to a stabilising head support for use by a patient during MRI scanning. The head support includes a shell and an inflatable bladder that is located at least partially within the shell. During use, the shell is located within an MRI magnet and the bladder is inflated about the patient's head to help hold the head steady during imaging.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A polymer composition for impregnating a high temperature superconductor (HTS) coil, the composition comprising: a polymer resin, a plurality of particles of a first filler material, and a plurality of particles of a second filler material; wherein the median particle size of the second filler material is less than the median particle size of the first filler material. The polymer composition may be used to prepare a polymer impregnated HTS coil having a predetermined turn-to-turn spacing. A property of the polymer composition may also be modified, for example, the coefficient of thermal contraction and/or resistivity of the composition. Also disclosed is a polymer impregnated HTS coil and a method for preparing the coil.
The present invention encompasses non-ribosomal peptides and non-ribosomal peptide synthetases, and the preparation and use thereof. Specifically encompassed are methods for preparing non-ribosomal peptide synthetases, methods for preparing non-ribosomal peptides from these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A modular and hierarchical DNA assembly platform for synthetic biology is described. This enabling technology, termed MIDAS (for Modular Idempotent DNA Assembly System), can precisely assemble multiple DNA fragments in a single reaction using a standardised assembly design. It can be used to build genes from libraries of sequence-verified, reusable parts and to assemble multiple genes in a single vector. We describe the design and use of MIDAS, and its application in the reconstruction of the metabolic pathway for production of paspaline, a key intermediate in the biosynthesis of a range of indole diterpenes—a class of economically important secondary metabolites produced by several species of filamentous fungi.
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists of Formula I. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 407/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 407/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
66.
COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
VICTORIA UNIVERSITY OF WELLINGTON (Nouvelle‑Zélande)
Inventeur(s)
Hermans, Ian Francis
Painter, Gavin Frank
Anderson, Regan James
Compton, Benjamin Jason
Gulab, Shivali Ashwin
Abrégé
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons
C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
A01N 63/30 - Champignons microscopiquesSubstances produites par des champignons microscopiques ou obtenues à partir de ceux-ci
An aspect of the invention provides a classification system (100) configured to classify at least one data point within a data set (106). The system comprises a first machine learning model (110) in which is maintained a first plurality of data points associated to respective first labels; a second machine learning model (112) in which is maintained a second plurality of data points associated to respective second labels; and a (classifier 114). The classifier (114) is configured to: classify the at least one data point using the first machine learning model (110) to a first confidence level to determine at least one first classification label; responsive to the first confidence level having a value greater than or equal to a classification threshold value: classifying the at least one data point with the at least one first classification label to the first confidence level; and responsive to the first confidence level having a value of zero and/or the first confidence level having a value below the classification threshold value: classifying the at least one data point using the second machine learning model to a second confidence level to determine at least one second classification label, responsive to the first confidence level having a value less than the second confidence level: classifying the at least one data point with the at least one second classification label, and responsive to the first confidence level having a value greater than or equal to the second confidence level: classifying the at least one data point with the at least one first classification label to the second confidence level.
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Business management; business administration; business
services, namely business advice, business management,
business administration, business consultancy, and business
information services, all relating to technology
commercialisation and transfer, evaluation of technologies
and assessing commercial potential, and establishment of new
businesses and companies; business consultation, business
information and business advisory services, including, but
not limited to, such services provided in relation to
technology transfer, commercialisation of technology,
research and development of products and processes, and
intellectual property assessment; developing and
facilitating business networks, including, but not limited
to, connecting university researchers, staff and students
with business mentors and advisors; business networking and
career networking services; negotiation of commercial
transactions for third parties, including, but not limited
to, the negotiation of agreements, assignments, contracts,
deeds and licences; market analysis and market research
services; sponsorship search services; and advertising,
promotional, and marketing services, including, but not
limited to, such services relating to technology transfer,
commercialisation of technology, research and development of
products and processes, and intellectual property
assessment; business research and evaluations; providing
advice, consultancy, and information relating to the
foregoing. Charitable fundraising services and fundraising activities,
including, but not limited to, charitable fundraising for
research purposes, technology commercialisation and
transfer; financial sponsorship services, including, but not
limited to, charitable sponsorship of research into health,
medicine, biotechnology, energy, environment, materials
science, electronic devices and instrumentation,
engineering, and computer software; fund distribution
services; financial grant services; and providing
information and advice about charitable fundraising services
and activities, sponsorship services, fund distribution
services, and financial grant services; providing advice,
consultancy, and information relating to the foregoing. Education and training services, including, but not limited
to, capacity building of national and local governments in
the fields of good governance, education, and health;
english language training for officials; education and
training to enhance leadership and management skills;
education and training in relation to government and public
sector reform, digital government, education, health and
wellbeing, innovation, good governance, environmental
services, management, organisational structures, technology
commercialisation and transfer, business, entrepreneurship,
intellectual property, and other commercial activities;
teaching, mentoring and coaching services; arranging and
conducting of lectures, seminars, workshops, conferences,
colloquiums, congresses and symposiums, including, but not
limited to, in respect of topics relating to science and
research, business management, technology commercialisation,
intellectual property, and other commercial activities;
production of audio recordings, video recordings,
audio-visual recordings, multimedia, radio programmes,
television programmes and video film, including, but not
limited to, in respect of topics relating to technology
commercialisation and transfer, business, entrepreneurship,
intellectual property, and other commercial activities;
providing information and advice about education and
training services; and program design, providing advice,
consultancy, and information relating to the foregoing. Scientific and technological services and research and
design relating thereto; industrial analysis and industrial
research services; design and development of computer
hardware and software; research relating to science,
industry, and technology, including, but not limited to,
health research, medical research, biotechnology research,
energy research, environmental research, materials science
research, electronic device and instrumentation research,
engineering research, and computer software research;
technological research; co-operative scientific and
industrial research, including, but not limited to,
cooperation amongst researchers and interaction between
research and industry sectors; industrial research of new
products and processes; scientific, industrial, and
technology research and development services for others;
preparation of reports relating to research, including, but
not limited to, reports regarding the outcomes of medical
and scientific research; and providing information and
advice about scientific, industrial, and technology research
services; providing advice, consultancy, and information
relating to the foregoing. Licensing of research and development activities; advisory
services relating to intellectual property rights,
protection and licensing; advisory services and consultancy
relating to intellectual property, technology transfer and
research and development; arranging for the provision of
legal services; legal services relating to the creation,
registration, and exploitation of intellectual property
rights; information services relating to intellectual
property matters; intellectual property consultancy;
investigations in relation to intellectual property;
licensing of intellectual property rights and research and
development; management of intellectual property; legal
research; research relating to intellectual property;
services for the exploitation of intellectual property
rights and inventions; providing advice, consultancy, and
information relating to the foregoing.
09 - Appareils et instruments scientifiques et électriques
Produits et services
Batteries; electrical cells; electric accumulators; electric
actuators; electric power supply units; electric power
storage apparatus; rechargeable batteries; aluminium-ion
batteries; anodes; cathodes; battery cables, chargers,
holders, leads, packs, plates and terminals; apparatus and
instruments for conducting, switching, transforming,
accumulating, regulating or controlling the use of
electricity; scientific apparatus and instruments; battery
cell packs; drone batteries; vehicle batteries; batteries
for lighting; mobile phone batteries; grid storage
batteries; residential batteries; consumer electronic
batteries; e-bike batteries; micromobility batteries; boat
batteries; and ship batteries.
Disclosed are electrolyte compositions for electrochemical devices, where the electrolyte compositions comprise a microemulsion and where the microemulsion comprises an aqueous phase and a water-immiscible phase. Also disclosed are microemulsion electrolyte compositions for electrically rechargeable electrochemical energy storage devices, including ion batteries (such as lithium ion, sodium ion, magnesium ion, calcium ion, and aluminium ion batteries), redox flow batteries and supercapacitors.
The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical additives for insecticides; chemical additives for
pesticides; chemical additives for use in the manufacture of
pharmaceuticals; active chemical ingredients for use in the
manufacture of insecticides; active chemical ingredients for
use in the manufacture of pesticides; active chemical
ingredients for use in the manufacture of pharmaceuticals;
active chemical ingredients for use in the manufacture of
plant protection agents; catalysts for use in biochemical
processes; catalysts for chemical and biochemical processes;
chemicals for use in biotechnological manufacturing
processes; chemicals for use in biotechnological product
development; enzymes derived from biotechnological processes
for use in industry; nucleic acids for scientific purposes;
nucleic acids for synthetic purposes; preparations for
protecting plants against pests or pathogens. Insecticides; pesticides; fungicides; parasiticides;
chemical preparations for treating diseases affecting crops;
chemical preparations for treating diseases affecting
plants; pharmaceuticals; active pharmaceutical ingredients
and active veterinary ingredients for the treatment of human
and animal diseases and medical conditions; antibiotics. Scientific research and development; scientific and
technological services; scientific and technological
services and research and design relating thereto;
scientific and technological services and research and
development relating thereto; scientific and medical
research and development; scientific research in the field
of genetics and genetic engineering; genetic engineering
services; oligonucleotide synthesis; agrochemical research
and development; biological research and analysis;
biological research and development; biological synthesis;
biotechnological research; synthesis of active chemical
ingredients for use in the manufacture of insecticides,
pesticides, plant protection agents and pharmaceuticals;
biological, pharmaceutical, veterinary and medical research.
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Business management; business administration; business services, namely, business advice, business management, business administration, business consultancy, and business information services, all relating to technology commercialisation and transfer, evaluation of technologies and assessing commercial potential, and establishment of new businesses and companies; business consultation, business information and business advisory services, in particular, such services provided in relation to technology transfer, commercialisation of technology, research and development of products and processes, and intellectual property assessment; developing and facilitating business networks by providing business networking, in particular, for university researchers, staff and students with business mentors and advisors; business networking and career networking services; negotiation of commercial transactions for third parties, in particular, the negotiation of agreements, assignments, contracts, deeds and licences; market analysis and market research services; sponsorship search services; and advertising, promotional, and marketing services, in particular, such services relating to technology transfer, commercialisation of technology, research and development of products and processes, and intellectual property assessment; business research and evaluations; providing advice, consultancy, and information relating to the foregoing Charitable fundraising services and organizing fundraising activities for the benefit of research purposes, technology commercialisation and transfer; sponsorship services, in particular, charitable sponsorship of research into health, medicine, biotechnology, energy, environment, materials science, electronic devices and instrumentation, engineering, and computer software; charitable fund distribution services; financial grant services for research into health, medicine, biotechnology, energy, environment, materials science, electronic devices and instrumentation, engineering and computer software; and providing information and advice about charitable fundraising services and charitable fundraising activities, charitable sponsorship services, charitable fund distribution services, and financial grant services; providing advice, consultancy, and information relating to the foregoing Education, namely, providing seminars, workshops and training in particular, on capacity building of national and local governments in the fields of good governance, education, and health; English language training for officials; education, namely, providing seminars, workshops and training in the field of enhancing leadership and management skills; education, namely, providing seminars, workshops and training in the field of government and public sector reform, digital government, business education, health and wellbeing, innovation, good governance, environmental services, management, organisational structures, technology commercialisation and transfer, business, entrepreneurship, intellectual property, and other commercial activities; teaching, mentoring and coaching services in the field of entrepreneurship; arranging and conducting of lectures, seminars, workshops, conferences, colloquiums, congresses and symposiums, in particular, in the field of science and research, business management, technology commercialisation, intellectual property, and other commercial activities; production of audio recordings, video recordings, audio-visual recordings, multimedia, radio programmes, television programmes and video film, in particular, on topics relating to technology commercialisation and transfer, business, entrepreneurship, intellectual property, and other commercial activities; providing information and advice about education and training services; program design in the nature of developing curriculum for educators; providing advice, consultancy, and information relating to the foregoing Scientific and technological services, namely, research and design in the fields of science, medicine and engineering; industrial analysis and industrial research in the field of science, medicine and engineering; design and development of computer hardware and software; research in the fields of science, industry, and technology, in particular, health research, medical research, biotechnology research, energy research, environmental research, materials science research, electronic device and instrumentation research, engineering research, and computer software research; technological research in the fields of science, medicine and engineering; co-operative scientific research and industrial research in the fields of medicine and engineering featuring cooperation amongst researchers and interaction between research and industry sectors; industrial research of new products and processes; scientific, industrial, and technology research and development of new products for others; preparation of medical and scientific reports relating to research, in particular, reports regarding the outcomes of medical and scientific research; providing information and advice about scientific research, industrial research and technology research in the fields of biology, chemistry, biomedicine and medicine; providing advice, consultancy, and information relating to the foregoing Licensing of intellectual property rights for new product research and development activities; advisory services relating to intellectual property rights, protection and licensing; legal advisory services and legal consultancy relating to intellectual property, technology transfer and research and development; arranging for the provision of legal services, namely, legal document preparation services and legal advisory services; establishment and exploitation in the nature of legal research in the field of intellectual property rights; information services relating to intellectual property matters; intellectual property consultancy; investigations in relation to intellectual property, namely, intellectual property watch services; licensing of intellectual property rights, intellectual property research and intellectual property development; licensing of software for management of intellectual property; legal research; legal research relating to intellectual property; legal research services for the exploitation of intellectual property rights and inventions; providing advice, consultancy, and information relating to the foregoing
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical additives for insecticides; chemical additives for
pesticides; chemical additives for use in the manufacture of
pharmaceuticals; active chemical ingredients for use in the
manufacture of insecticides; active chemical ingredients for
use in the manufacture of pesticides; active chemical
ingredients for use in the manufacture of pharmaceuticals;
active chemical ingredients for use in the manufacture of
plant protection agents; catalysts for use in biochemical
processes; catalysts for chemical and biochemical processes;
chemicals for use in biotechnological manufacturing
processes; chemicals for use in biotechnological product
development; enzymes derived from biotechnological processes
for use in industry; nucleic acids for scientific purposes;
nucleic acids for synthetic purposes; preparations for
protecting plants against pests or pathogens. Scientific research and development; scientific and
technological services; scientific and technological
services and research and design relating thereto;
scientific and technological services and research and
development relating thereto; scientific and medical
research and development; scientific research in the field
of genetics and genetic engineering; genetic engineering
services; oligonucleotide synthesis; agrochemical research
and development; biological research and analysis;
biological research and development; biological synthesis;
biotechnological research; synthesis of active chemical
ingredients for use in the manufacture of insecticides,
pesticides, plant protection agents and pharmaceuticals;
biological, pharmaceutical, veterinary and medical research.
A magnet (7) for use in an apparatus (1) for performing magnetic resonance imaging (MRI) of a patient's head is an asymmetric magnet (7) comprising a plurality of coils (45, 46, 47) that are aligned along a cylindrical axis (29) to provide a magnetic field on the cylindrical axis (29). The magnet (7) has a patient end (23) arranged to be positioned adjacent or against a patient's shoulders with the patient's shoulders outside the magnet (7). The magnet has a recess (27) for receipt of the patient's head and extending into the magnet (7) from the patient end (23). The magnet (7) is configured to provide an imaging volume (35) that is positioned along the cylindrical axis (29) of the magnet (7) in the recess (27), and at least a major part of the imaging volume (35) has a substantially linear non-zero magnetic field gradient along the cylindrical axis (29).
G01R 33/381 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des électro-aimants
G01R 33/38 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01R 33/3815 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des électro-aimants avec des bobines supraconductrices, p. ex. leurs alimentations
G01R 33/421 - Blindage du champ magnétique principal ou du champ magnétique à gradient
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
79.
Rare earth nitride structures and devices and method for removing a passivating capping
The present invention concerns a structure or device comprising a rare earth nitride material, and a removable capping for passivating the rare earth nitride material.
H01L 43/02 - Dispositifs utilisant les effets galvanomagnétiques ou des effets magnétiques analogues; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails
H01F 1/03 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité
Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical compositions, methods for inhibiting DNA methyltransferase 1, and methods for treating cancer. The inhibitors are compounds of the general formula.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
An optical fibre sensing system (300) with an incident light source (309), a wavelength spectrum interrogator (313), and an optical fibre (302) with a substantially continuous fibre Bragg grating (306). An upstream portion (318) of the optical fibre has an attenuation length to light to the interrogator (313) at a first equilibrium wavelength. A downstream portion (322) of the optical fibre reflects light to the interrogator (313) when a change in temperature and/or strain at the downstream portion (322) causes a portion of the fibre Bragg grating to reflect light to the interrogator (313) at a second wavelength and at a second intensity. A processor (315) is configured to analyse the reflected spectrum (314) to determine when a portion of the fibre Bragg grating (306) is experiencing a change in temperature and/or strain based on deviation in the reflected spectrum (314) from an initial peak corresponding to the initial wavelength.
G01K 11/32 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant des changements dans la transmittance, la diffusion ou la luminescence dans les fibres optiques
G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p. ex. par l'analyse des contraintes par photo-élasticité
An asymmetric magnet for use in performing MRI of a patient's head. The magnet has a patient end. The magnet provides an offset imaging volume (35) in a recess with an isocentre that is positioned closer to the patient end than an opposite end. The magnet has at least three groups of coils (44, 45, 46) in a generally tapering arrangement. The magnet also has an additional group of coils (47). A first group of coils (44) overlaps the additional group of coils (47), such that a bottom portion (47") of the additional group of coils (47) is positioned closer to the patient end of the magnet than a top portion (44') of the first group of coils (44).
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical additives for insecticides; chemical additives for pesticides; active chemical ingredients for use in the manufacture of insecticides; active chemical ingredients for use in the manufacture of pesticides; active chemical ingredients for use in the manufacture fungicides and parasiticides; active chemical ingredients for use in the manufacture of plant protection agents; genetically engineered catalysts for use in biochemical processes; genetically engineered catalysts for chemical and biochemical processes; chemicals for use in genetically engineered biotechnological manufacturing processes; chemicals for use in genetically engineered biotechnological product development; genetically engineered enzymes derived from biotechnological processes for use in industry, namely in animal health, and crop protection; nucleic acids for scientific purposes, for use in animal health and crop protection; nucleic acids for synthetic purposes, animal and health, crop protection, and pharmaceuticals not for medical purposes; preparations for protecting plants against pests or pathogens Scientific research and development, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; scientific and technological services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and,crop protection; scientific and technological services and research and design relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; scientific and technological services and research and development relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection scientific and medical research and development, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; genetic engineering services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; agrochemical research and development; biological research and analysis; biological and chemical research services especially in the fields of chemical and biological synthesis of compounds, in particular of biomolecules, and the purification methods of synthesis compounds, in particular biomolecules; genetically engineered biological synthesis of active chemical ingredients for use in the manufacture of insecticides, pesticides, and plant protection agents; biological veterinary and medical research
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical additives for insecticides; chemical additives for pesticides; chemical additives for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of insecticides; active chemical ingredients for use in the manufacture of pesticides; active chemical ingredients for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of plant protection agents; catalysts for use in biochemical processes; catalysts for chemical and biochemical processes; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; nucleic acids for scientific purposes; nucleic acids for synthetic purposes; preparations for protecting plants against pests or pathogens Insecticides; pesticides; fungicides; parasiticides; chemical preparations for treating diseases affecting crops; chemical preparations for treating diseases affecting plants; pharmaceuticals for the treatment of blood feeding arthropods, cancer, bacterial infections, and influenza infection; active pharmaceutical ingredients and active veterinary ingredients for the treatment of human and animal diseases and medical conditions namely for the treatment of blood feeding arthropods, cancer, bacterial infections, and influenza infection; antibiotics Scientific research and development; scientific and technological services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and technological services and research and design relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell [ ines ] * lines * or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and technological services and research and development relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and medical research and development; scientific research in the field of genetics and genetic engineering; genetic engineering services; agrochemical research and development; biological research and analysis; biological research and development; biological synthesis; biotechnological research; synthesis of active chemical ingredients for use in the manufacture of insecticides, pesticides, plant protection agents and pharmaceuticals; biological, pharmaceutical, veterinary and medical research
The present invention relates generally to methods of using nalmefene for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalmefene for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalmefene for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A rendering process and system that may be used to composite virtual objects in panoramic video to provide a virtual reality and augmented reality experience. The process includes receiving low dynamic range (LDR) video data, e.g. 360° video; generating radiance maps, such as diffuse and specular maps, from the LDR data; inverse tone mapping the LDR data of the maps to generate high dynamic range (HDR) data for the maps; and receiving at least one virtual object and applying image based lighting (IBL) to the virtual object using the HDR data of the maps. A perceptually based threshold is also applied to radiance maps to detect prominent pixels, and using the prominent pixels as salient lights for image based shadowing (IBS) associated the virtual object. Objects are composited 360° video in real time using IBL and IBS without precomputation allowing user interaction with the objects.
An optical system for narrowing the bandwidth of a beam of incident radiation comprises an optical mixing unit configured to receive a first beam of radiation and a second beam of radiation. The first and second beams are spatially chirped and the first beam is inverted relative to the second beam. The optical mixing unit comprises an optical mixing member comprising a nonlinear optical medium to mix the first and second beams into an output beam having a narrower bandwidth than the beam of incident radiation.
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
A system for determining a relative position associated to a first receiver and a second receiver includes a code module 402 configured to receive location data associated to the first receiver, receive location data associated to the second receiver, and determine a first estimate relative position associated to the first receiver and the second receiver; a float module 404 configured to determine a second estimate relative position associated to the first receiver and the second receiver at least partly from the first estimate relative position; a fix module 406 configured to determine a third estimate relative position associated to the first receiver and the second receiver at least partly from the second estimate relative position; and a sidereal module 408 configured to determine a fourth estimate relative position associated to the first receiver and the second receiver at least partly from the third estimate relative position.
G01S 19/44 - Résolution de l'ambiguïté de la phase de la porteuseAmbiguïté flottanteProcédé LAMBDA [compensation par les moindres carrés de la décorrélation de l'ambiguïté]
The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
C07H 13/08 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés directement à des carbocycles
C07H 13/04 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés à des atomes de carbone acycliques
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
The invention relates to branched trehalose glycolipids of Formula (I) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
A computer-implemented method to capture and detect clusters in, or determined by, a set V of discrete digital data comprising; computing, from the set V, an abstract separation system ASS that consists of a finite set S, whose elements are called separations; of a predetermined transitive, antisymmetric and reflexive order relation ≤ on S; and of an order-reversing involution *: S→S, that is, a mapping s→s* with the property that, (s*)*=s and that r≤s implies s*
G06V 10/62 - Extraction de caractéristiques d’images ou de vidéos relative à une dimension temporelle, p. ex. extraction de caractéristiques axées sur le tempsSuivi de modèle
G06F 18/23213 - Techniques non hiérarchiques en utilisant les statistiques ou l'optimisation des fonctions, p. ex. modélisation des fonctions de densité de probabilité avec un nombre fixe de partitions, p. ex. K-moyennes
A rendering process, including receiving an input image and applying a light feature detection process to the input image to generate light feature parameters for the input image; accessing a radiance map database using the light feature parameters to select a radiance map; and rendering an output image with a virtual scene and lighting the output image using the selected radiance map. The light feature parameters are of a dominant light feature vector representing dominant lights and an ambient light feature vector representing ambient light of the input image. A light feature index for the radiance map database is generated by processing an input panoramic image using a light feature detection process to generate the light feature parameters associated with the input panoramic image; and using the light feature parameters as the index for the panoramic image in the database. The database provides an illumination space comprising the light feature index.
G06F 16/20 - Recherche d’informationsStructures de bases de données à cet effetStructures de systèmes de fichiers à cet effet de données structurées, p. ex. de données relationnelles
Nodulisporic acids (NAs) comprise a group of indole diterpenes known for their potent insecticidal activities; however, biosynthesis of NAs by its natural producer, Hypoxylon pulicicidum (Nodulisporium sp.) is exceptionally difficult to achieve. The identification of genes responsible for NA production could enable biosynthetic pathway optimization to provide access to NAs for commercial applications. Obtaining useful quantities of NAs using published fermentations methods is challenging, making gene knockout studies an undesirable method to confirm gene function. Alternatively, heterologous gene expression of H. pulicicidum genes in a more robust host species like Penicillium paxilli provides a way to rapidly identify the function of genes that play a role in NA biosynthesis. In this work, we identified the function of four secondary-metabolic genes necessary for the biosynthesis of nodulisporic acid F (NAF) and reconstituted these genes in the genome of P. paxilli to enable heterologous production of NAF in this fungus.
C12P 1/02 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des champignons
A modular and hierarchical DNA assembly platform for synthetic biology is described. This enabling technology, termed MIDAS (for Modular Idempotent DNA Assembly System), can precisely assemble multiple DNA fragments in a single reaction using a standardised assembly design. It can be used to build genes from libraries of sequence-verified, reusable parts and to assemble multiple genes in a single vector. We describe the design and use of MIDAS, and its application in the reconstruction of the metabolic pathway for production of paspaline, a key intermediate in the biosynthesis of a range of indole diterpenes — a class of economically important secondary metabolites produced by several species of filamentous fungi.
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
Nodulisporic acids (NAs) comprise a group of indole diterpenes known for their potent insecticidal activities; however, biosynthesis of NAs by its natural producer, Hypoxylon pulicicidum (Nodulisporium sp.) is exceptionally difficult to achieve. The identification of genes responsible for NA production could enable biosynthetic pathway optimization to provide access to NAs for commercial applications. Obtaining useful quantities of NAs using published fermentations methods is challenging, making gene knockout studies an undesirable method to confirm gene function. Alternatively, heterologous gene expression of H. pulicicidum genes in a more robust host species like Penicillium paxilli provides a way to rapidly identify the function of genes that play a role in NA biosynthesis. In this work, we identified the function of four secondary-metabolic genes necessary for the biosynthesis of nodulisporic acid F (NAF) and reconstituted these genes in the genome of P. paxilli to enable heterologous production of NAF in this fungus.
C12P 1/02 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des champignons
A01N 63/04 - Champignons microscopiques; Substances produites par, ou obtenues à partir de champignons microscopiques
The invention relates to peptide conjugates of Formula (I). The peptide conjugates of the invention have activity as MAIT agonists. The peptide conjugates of the invention also enhance immune responses and therefore are effective vaccines and vaccine adjuvants. The invention also relates to methods and uses of such conjugates.
C07D 239/545 - Deux atomes d'oxygène liés par une liaison double ou sous forme de radicaux hydroxyle non substitués avec d'autres hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone du cycle
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
